In this Breast Cancer Management review, find out more about predictive biomarkers for immunotherapy response in breast cancer patients.
Immunotherapy using anti-PD(L)1 has revolutionized treatment for various tumor types. Early data have shown durable responses in a small subgroup of breast cancer patients. So far, the response rates appear higher for breast tumors that are triple negative, PDL1-positive and/or harbor high levels of immune cells. Both comprehensive analyses of the breast tumor microenvironment and exploiting research on biomarkers in other cancer types, such as melanoma and lung cancer, may contribute to the discovery of accurate biomarkers to select breast cancer patients for immunotherapy. In this review from Breast Cancer Management, learn how insights from the breast tumor microenvironment and predictive biomarkers from other cancers could enable personalized breast cancer immunotherapy.
Access the paper through
Voorwerk L, Kat M, Kok M. Towards predictive biomarkers for immunotherapy response in breast cancer patients. Breast Cancer Manag. https://doi.org/10.2217/bmt-2017-0014 (2018)(Epub ahead of print)